Your shopping cart is currently empty

RGD-DA6 is an αvβ3-targeting ligand composed of RGDfK (an RGD peptide targeting integrin αvβ3), DOTADG, d-Glu, Lys, AMBA, and IPBA. Through radiolabeling, RGD-DA6 forms an αvβ3-targeted radioligand for high-contrast tumor imaging and improved anticancer efficacy.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | RGD-DA6 is an αvβ3-targeting ligand composed of RGDfK (an RGD peptide targeting integrin αvβ3), DOTADG, d-Glu, Lys, AMBA, and IPBA. Through radiolabeling, RGD-DA6 forms an αvβ3-targeted radioligand for high-contrast tumor imaging and improved anticancer efficacy. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.